World leader in probiotics
BioGaia’s products are sold in around 90 countries. The largest segment is paediatrics, accounting for over 80 per cent of total sales. Our focus is on finished consumer products that are sold under our own BioGaia brand. In 2015 these sales, including co-branding, accounted for over 60 per cent of sales of finished consumer products. The strategy is to continuously increase the share of products sold under the BioGaia brand.
Our products combine the well researched probiotic bacteria Lactobacillus reuteri with top of the line engineering to develop unique packaging solutions and create probiotic products that match consumer needs. Lactobacillus reuteri is a “good” and friendly bacterium that helps battle the “bad” microorganisms in the digestive tract.
BioGaia in short
- Founded in 1990
- 118 employees
- Offices in Sweden, Stockholm, Lund, Eslöv, USA, Japan
- Products in 90 markets through distributors
- Around 60 distribution partners
- Net sales amounted to SEK 534.7 in 2016
- Listed on the Nasdaq Stockholm (mid cap list)
- Holds 440 patents in 32 families
Business mission: BioGaia conducts research and development to provide consumers with clinically proven, health-promoting, patented and user-friendly probiotic products.
Positioning: Dietary supplements containing scientifically tested probiotics of a high quality that are sold in pharmacies and similar sales outlets. In most markets, the products are recommended by doctors or other healthcare professionals.
Vision: BioGaia’s vision is to be a ground-breaking leader in probiotics. Read more about our Mission and vision.
Strategy: BioGaia’s strategy rests on five cornerstones: Growth, Customer Focus, Operational Excellence, Innovation and Sustainability. It is based on the following:
- Conducting high quality clinical studies
- Developing innovative new products and
- Providing our partners with effective support,
among other things by participating in international
medical conferences, hosting seminars,
training sales staff and providing marketing
materials based on clinical studies.
- Having dedicated and skilled employees who
challenge the existing solutions.
Headquarters, with executive management, administrative functions and marketing and sales are based in Stockholm. Product development and departments for production and quality control are based in Lund. Sales offices are also based in Tokyo, Hiroshima and Miami, USA.
Thanks to a successful business model, BioGaia has been able to grow globally with a lean, efficient and agile organization. The business model will also be a key enabler for BioGaia’s ongoing expansion. BioGaia’s business model is based on three external networks – research, production and distribution.
In the research area there are collaborations with more than 50 research institutions and clinics.
The products are manufactured and packaged at six different facilities in Europe and the USA. Trough close and long-term collaboration, it is possible to continuously optimize production and logistic. The suppliers – above all the subsidiary BioGaia Production – are also important partners for product development, both in creating new products and enhancing existing ones.
The distribution network consists of around 60 partners with sales in some 90 countries. Most of these companies have sales representatives who visit doctors and other healthcare professionals. By informing them about the published results of clinical studies, the representatives create interest, knowledge and confidence among doctors who then recommend the products to their patients, who in turn buy the products in pharmacies and similar sales outlets. BioGaia’s products are available at drug stores and pharmacies around the world.